Cooling caps cut chemo hair loss: US study
Cooling caps cut chemo hair loss: US study
Another update on the great success of our DigniCap Cooling System in Western Australia
“For the first 3 weeks after chemo & use of the DigniCap I didn’t experience any hair loss whatsoever. In fact, very surprisingly, my hair started to grow back! After 4 weeks of chemo, my hair was 8 millimetres long, & at the end of my chemo, 9 weeks later, my hair was 27 mm long!” – Belinda, 40, forensic scientist & avid cyclist, Perth
“Those entering our trial believe they will not only reap personal benefits, but will also be helping the next generaton of women undergoing chemotherapy” – – Prof Arlene Chan, Breast Medical Oncologists, Director Breast Clinical Trials Unit
For more information please go to
SYDNEY, Australia. Aurora BioScience Pty. Ltd. today announced that it has entered into a sales and marketing distribution agreement for Australia and New Zealand with BiaCare, a leading provider of lymphoedema compression garments.
Aurora BioScience entered into a distribution agreement in December 2015; under the agreement Aurora Bioscience will be responsible for the sales, marketing, clinical support and distribution in both the Australian and New Zealand markets.
BiaCare is dedicated to helping meet the challenge of oedema with products that produce positive outcomes and improve the quality of life.
With well over 10 years of experience in manufacturing innovative compression garments, BiaCare is a diverse group of people, ranging from clinical professionals, engineers, marketing associates and design and production experts. All bring a unique set of talents to the table and share a common vision of providing the best therapeutic solutions available.
“The BiaCare range of compression garments are a truly innovative and important product line for the treatment of oedema, especially in the area of lymphoedema; these products have the potential to significantly improve the lives of patients” said Darren Banks, Managing Director of Aurora BioScience.
The BiaCare range includes compression garments for both lymphoedema and wound care, a full range of accessories as well as bandages, foams and other consumable items.
“We are extremely excited to be launching such an innovative and quality range in Australia and New Zealand and believe that the BiaCare products can have a significant impact on patient lives” stated Mr. Banks.
About Aurora BioScience Pty Ltd
Located in Sydney Australia, Aurora BioScience is committed to providing advanced, high quality medical devices and healthcare products to assist medical professionals within Australia, New Zealand and the Pacific Islands healthcare markets, to contribute to the enhancement of patient’s quality of life. Our areas of interest include lymphoedema, cancer therapies, neurology, pulmonology, and haematology and blood products.
For more information, please visit www.aurorabioscience.com.au
The prefix “Bia” is of Greek origin and means “life”, similar to “Bio”. The name BiaCare captures, in a single word, the driving force of the company – to care about life. As we all know, life is full of physical challenges. BiaCare is dedicated to helping meet those challenges with products that produce positive outcomes, and improve the quality of life. BiaCare is located in Zeeland, Michigan, U.S.A.
For more details on the success of the DigniCap system at Cabrini Hospital, please see the story in the Hospital Magazine “Connect” (click the following link)
Aurora BioScience recently received a wonderful letter from a lady, Marie, who recently used the DigniCap at Cabrini Brighton in Melbourne. Please see her letter below. If you are a patient or medical professional who would like to contact Marie or want more information on how the DigniCap can assist you, please contact Aurora BioScience on 1300 309 994
Aurora Bioscience, NSW
23rd November 2015
I am writing to you to thank you and to say how lucky I am to be one of the few women to use the DigniCap Scalp Cooling System while undergoing chemotherapy at Cabrini Brighton.
In April this year I was diagnosed with Secondary Breast Cancer and was advised that the most suitable treatment plan was chemotherapy. Without sounding shallow or vain, when my oncologist was discuss the treatment, I did not think of the harmful effects that Chemotherapy was going to have on my body, the only thing I thought of was the fear of losing my hair.
When I went to visit the chemo ward of the hospital, the nurse ran through how the Dignicap will work when I come in for my treatment. At the time it was recently trialled with a group of women at Cabrini Brighton and there were very positive results. I was initially concerned on how I would tolerate the cold temperature on my scalp, but was prepared to try it if it could save my hair.
When I arrived for my first chemotherapy treatment, the nurses fitting the cool cap and began the process of cooling my scalp. After the initial 2-3 min of discomfort, described more like a “brain freeze” I was pleasantly surprised that this initial feeling subsided and was quite comfortable during the duration of the chemo therapy treatment.
After undergoing 17 sessions of chemotherapy in conjunction with the scalp cooling system, I am so thrilled with the results and the minimal impact on my hair. I am still able to have my hair blow-waved weekly and my hairstylist even said that he has seen my hair thicken and some areas.
It’s hard enough facing the devastating diagnosis of Breast Cancer and having to undergo chemotherapy. What is really exciting is that now this new amazing technology is available to help reduce the physical and psychological impact of this treatment. It is my belief and hope that this new technology is embraced by more hospitals and medical practices to support women going through this life changing time.
(Cabrini Brighton Hospital patient)
Dignitana was present at the recent American Society of Clinical Oncology (ASCO) meeting in Chicago with the DigniCap® scalp cooling system taking centre stage.
A poster presentation entitled ‘Clinical Performance of the DigniCap® System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia – a multi centre trial” was extremely well received.
In addition, NBC America aired a wonderful segment about our scalp cooling system DigniCap® – and the powerfully positive impact it can have on patients and their families. Here’s the clip: http://nbcnews.to/1FLq6Ly
SYDNEY, Australia. Aurora BioScience Pty. Ltd. today announced that it has entered into an exclusive distribution agreement for Australia and New Zealand for the PhysioTouch® Negative Pressure treatment device for Oedema.
PhysioTouch® is a revolutionary new treatment for oedema comprised of a negative pressure device which allows vertical and horizontal stretching of the fascial (connective tissue) structures, expanding the space for circulation of blood and lymph. The results of PhysioTouch® therapy are immediately measurable as reduced swelling, reduced pain and improved range of motion.
PhysioTouch® uses a vacuum where the pressure, pulsation, and vibration can be precisely controlled. PhysioTouch® expands and stretches the skin and the tissue underneath, pulling anchor fibres to dilate the endothelial openings of the lymphatic capillaries. Simultaneously, the expansion of fascial and connective tissue structures creates space for blood circulation and lymph flow.
The vacuum created by PhysioTouch® causes fluid to flow from the higher pressure area towards the lower pressure area. Metabolic waste flows from interstitial space through lymphatic capillaries and pre-collectors to the lymphatic collectors. In addition, the pumping mechanism of the lymphatic collectors is activated causing the lymph flow to increase further.
Aurora BioScience entered into an exclusive distribution agreement in May 2015; under the agreement Aurora Bioscience will be exclusively responsible for the sales, marketing and distribution in both the Australian and New Zealand markets.
“The PhysioTouch® device is a truly innovative and important medical advancement for the treatment of oedema, especially in the area of lymphoedema; it has the potential to significantly improve the lives of patients” said Darren Banks, Managing Director of Aurora BioScience.
The PhysioTouch® device was developed by HLD Healthy Life Devices Ltd, a pioneering Finnish healthcare technology company.
“We are extremely excited to be launching such an innovative product as the PhysioTouch® and believe that it can have a significant impact of patient’s lives here in Australia and New Zealand. The product will be launched at the Australian Lymphology Association meeting in Adelaide on 30th May. It will also be demonstrated at the Cancer Nurses Society of Australia meeting in Perth in June”. stated Mr. Banks.
For more information about PhysioTouch, please visit click here
About Aurora BioScience Pty Ltd
Located in Sydney Australia, Aurora BioScience is committed to providing advanced, high quality medical devices and healthcare products to assist medical professionals within Australia, New Zealand and the Pacific Islands healthcare markets, to contribute to the enhancement of patient’s quality of life. Our areas of interest include cancer therapies, neurology, pulmonology, and haematology and blood products.
For more information please go to www.aurorabioscience.com.au
About HLD Healthy Life Devices.
HLD Healthy Life Devices Ltd, a pioneering Finnish healthcare technology company. The treatment method it has developed represents the newest technology in the field. Their therapy devices are already in use at approximately three hundred locations in various parts of Finland, Europe and the USA. The HLD medical devices have established their place in the toolkit of healthcare professionals. They can be used to significantly improve patients’ quality of life by reducing pain and swelling and improving range of motion. HLD is a rapidly growing company aiming to strongly increase our share in international markets.
Pivotal trials using Cambridge UK medical technology to fight breast cancer are underway at six sites across the United States.
Endomag’s magnetic detection system is under the microscope at the University of California San Francisco and five other sites across the US, including MD Anderson Cancer Center, and will enrol up to 180 breast cancer patients.
The study follows the December approval of Endomag’s Investigational Device Exemption by the United States Food and Drug Administration.
The Cambridge company’s Sentimag and Sienna+ magnetic detection system is used during cancer staging in the Sentinel Lymph Node Biopsy (SLNB) procedure and allows surgeons to locate the lymph nodes that potentially harbour cancer with unprecedented sensitivity and accuracy.
To use the system, surgeons inject the Sienna+ magnetic tracer into the breast and then use the Sentimag handheld probe to find the sentinel nodes that have taken up the Sienna+.
The Endomag system avoids the radioisotopes traditionally used in cancer staging, offers patients a pain-free injection of tracer and gives surgeons more control.
Dr Peter Beitsch, of Dallas Surgical, who carried out the first Sentimag procedure in the US, said: “This is a breakthrough in sentinel node detection, allowing surgeons to localise nodes precisely and rapidly without any of the concerns associated with the use of radioactivity.
“This product has the potential to eliminate radioisotopes in sentinel node biopsy, simplifying the procedure for surgeons and making accurate staging more widely available.”
The system is approved for use in Europe and, since 2012, thousands of cancer patients across 12 European countries have benefited from the new technique. Published results from clinical trials with more than 1,000 breast cancer patients have shown that the Sentimag and Sienna+ system is safe and clinically equivalent to the current gold standard for sentinel lymph node detection.
The study aims to provide further clinical evidence that the solution is as safe and effective as the current standard of care with US patients.
Endomag’s products also allow the technique to be rolled out to all hospitals and clinics – even those without access to radioisotope handling facilities – making the procedure more accessible to everyone who needs it.
Endomag CEO Eric Mayes believes the US clinical trial will prove transformational to the company’s strategy to have the technology adopted as the worldwide gold standard for cancer patient care.
Some of the finest surgeons at cancer centres across the United States are involved in the trial, he added.
Copyright © Aurora Bioscience 2012. All rights reserved.
Norwest Web Design Orion Creative